Need a specific person's email?
Browse bioAffinity Technologies's employee directory (about 34 employees) and reveal verified emails free.
bioAffinity Technologies's most common email format is FL@bioaffinitytech.com (ex. JD@bioaffinitytech.com), used for 67% of bioaffinitytech.com addresses. bioAffinity Technologies uses 4 email patterns.
| Format | Example | Share of bioaffinitytech.com |
|---|---|---|
| FL@bioaffinitytech.comMost common | JD@bioaffinitytech.com | |
| First.Last@bioaffinitytech.com | John.Doe@bioaffinitytech.com | |
| FLast@bioaffinitytech.com | JDoe@bioaffinitytech.com | |
| Last@bioaffinitytech.com | Doe@bioaffinitytech.com |
Browse bioAffinity Technologies's employee directory (about 34 employees) and reveal verified emails free.
Biotechnology ResearchTexas, United States11-50 Employees
bioAffinity Technologies is a biotechnology research company focused on noninvasive diagnostics for lung disease, including early-stage lung cancer. Its primary product, CyPath Lung, is designed to detect early lung cancer with high sensitivity and specificity, particularly for patients who present with a pulmonary nodule after screening or imaging. The company positions its technology as a means to improve diagnostic accuracy, reduce unnecessary invasive procedures, and lower patient anxiety and medical costs by enabling earlier and more accurate detection. Based in San Antonio, Texas, bioAffinity Technologies operates in the biotechnology research sector and maintains a growing scientific advisory presence with recent appointments to its Medical and Scientific Advisory Board. The firm has engaged in external collaborations and outreach, including partnerships and presentations at professional gatherings, to advance developments in noninvasive lung diagnostics and related applications.
Most common format
FL@bioaffinitytech.com
Example: JD@bioaffinitytech.com
Free with a LeadIQ account. No credit card.
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.